Study to Assess the Safety and Tolerability of a PARP Inhibitor in Combination With Topotecan
The purpose of this study is to identify a safe and tolerable dose of the drug KU-0059436 that can be given in combination with topotecan chemotherapy in patients with advanced solid tumours
Malignant Solid Tumors
DRUG: KU-0059436 (AZD2281)(PARP inhibitor)|DRUG: Topotecan
To establish the maximum tolerated dose (MTD) of KU 0059436 in combination with topotecan, assessed at each visit
To identify the dose limiting toxicity of the combination therapy, assessed at each visit
The purpose of this study is to identify a safe and tolerable dose of the drug KU-0059436 that can be given in combination with topotecan chemotherapy in patients with advanced solid tumours